<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="116090">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02025868</url>
  </required_header>
  <id_info>
    <org_study_id>ANRS 12269 THILAO</org_study_id>
    <nct_id>NCT02025868</nct_id>
  </id_info>
  <brief_title>Third Line Antiretroviral Threatment Optimization in Sub-Saharan Africa</brief_title>
  <acronym>THILAO</acronym>
  <official_title>Systematic &quot;Adherence Intervention&quot; Phase Before Switching to 3rd-line ART in Patients With 2nd-line ART Virologic Failure in Sub-Saharan Africa : a Phase 2b Non-randomized Study.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>French National Institute for Health and Medical Research-French National Agency for Research on AIDS and Viral Hepatitis (Inserm-ANRS)</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>French National Institute for Health and Medical Research-French National Agency for Research on AIDS and Viral Hepatitis (Inserm-ANRS)</source>
  <oversight_info>
    <authority>Burkina Faso: Ministère de la santé</authority>
    <authority>Burkina Faso: Ministère de la Recherche Scientifique et de l'Innovation</authority>
    <authority>Burkina Faso: Comité d'Ethique pour la Recherche en Santé</authority>
    <authority>Cote d'Ivoire: Ministère de la Santé et de la Lutte contre le SIDA</authority>
    <authority>Cote d'Ivoire: Comité National d'Ethique et de la Recherche</authority>
    <authority>Mali: Ministère de la santé</authority>
    <authority>Mali: Comité d'Ethique de l'Institut National de Recherche en Santé Publique</authority>
    <authority>Senegal: Ministere de la Sante et de l'Action Sociale</authority>
    <authority>Senegal: Comité National d'Ethique pour la Recherche en Santé</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Thilao is a multi-country, phase 2b, non-randomized study, in Burkina Faso, Cote d'Ivoire,
      Mali and Senegal, West Africa.

      HIV-1 adults with 2nd-line ART virologic failure (plasma HIV-1 RNA &gt;1000 copies/ml) will be
      recruited and followed in two phases:

        -  First, a 12-week intentive adherence reinforcement phase, during which patients will
           continue 2nd-line ART, be seen repeatidly for counseling and educational training on
           adherence, and be offered the possibility of phone, SMS and home visit contacts with
           social workers;

        -  Second, a 48-week phase, during which:

             -  Patients successfully resuppressed at the end of the first phase will continue
                2nd-line ART and adherence reinforcement;

             -  Patients with persitent virologic failure will switch to a darunavir/r +
                raltegravir-based 3rd-line ART.

      Genotype resistance tests will be performed retrospectively on frozen samples. The main
      outcome will be the percentage of patients with plasma HIV-1 viral RNA &lt;50 copies/ml at 64
      weeks.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Main objective

      To estimate, in sub-Saharan African HIV-1 infected adults who failed a NNRTI-base first-line
      ART and then a PI-based second-line ART:

        1. The efficacy (and associated factors) at 12 weeks of an intensive 3-months adherence
           reinfrocement phase;

        2. In patients who successfully resuppress at 12 weeks: The percentage of patients still
           with continuing succesfull virologic supression on 2nd-line ART at 64 weeks (and
           factors associated to success) ;

        3. In patients with persistent failure at 12 weeks : The efficacy (and associated factors)
           at 64 weeks of a darunavir/r + raltegravir-based 3rd-line regimen.

      Number of participants : 200

      Main outcome :

        -  At 12 weeks : Proportion of patients with a plasma HIV-1 RNA &lt;400 copies/ml and/or with
           a decrease in plasma HIV-1 RNA &gt;2 log10 copies/ml between inclusion and 12 weeks;

        -  At 64 weeks : proportion of patients with a plasma HIV-1 RNA &lt;50 copies/ml.

      Inclusion criteria:

        -  Age &gt;18 years

        -  Documented HIV-1 infection.

        -  History of failing a NNRTI-based 1st-line ART

        -  Current PI-based 2nd-line ART &gt;6 months

        -  Plasma HIV-1 RNA &gt;1000 copies/ml

        -  Signed informed consent
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>March 2013</start_date>
  <completion_date type="Anticipated">June 2015</completion_date>
  <primary_completion_date type="Anticipated">June 2015</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Virologic efficacy of the adherence reinforcement intervention</measure>
    <time_frame>Week 12</time_frame>
    <safety_issue>No</safety_issue>
    <description>Proportion of patients with plasma viral load &lt;400 copies/ml at Week 12 and/or with a decrease in plasma viral load &gt;2 log10 copies/ml between inclusion and Week 12</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Persistent virologic efficacy of the adherence reinforcement intervention</measure>
    <time_frame>Week 64</time_frame>
    <safety_issue>No</safety_issue>
    <description>Proportion of patients with plasma viral load &lt;50 copies/ ml at Week 64 among those who stayed on 2nd-line ART at Week 16</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Virologic efficacy of 3rd-line ART</measure>
    <time_frame>Week 64</time_frame>
    <safety_issue>No</safety_issue>
    <description>Proportion of patients with HIV-1 plasma viral load &lt;50 copies/ml at Week 64 among those with persistent failure at Week 12 who switched to 3rd-line ART</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Immunological efficacy of the adherence reinforcement intervention</measure>
    <time_frame>Week 12</time_frame>
    <safety_issue>No</safety_issue>
    <description>CD4 count evolution between inclusion and Week 12</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Immunological efficacy of 3rd-line ART</measure>
    <time_frame>Week 64</time_frame>
    <safety_issue>No</safety_issue>
    <description>CD4 count evolution between Week12 and Week 64 among patients who switched to 3rd-line ART at Week 16</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tolerance of 3rd-line ART drugs</measure>
    <time_frame>Week 64</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Incidence of grade 3-4 adverse events (ANRS grading table) in patients on 3rd-line ART</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adherence  to 3rd-line ART</measure>
    <time_frame>Week 64</time_frame>
    <safety_issue>No</safety_issue>
    <description>3rd-line Medication Possession Ratio between Week 16 and Week 64</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Resistance to 1st and 2nd-line antiretroviral drugs</measure>
    <time_frame>Week 12</time_frame>
    <safety_issue>No</safety_issue>
    <description>Resistance mutations to antiretroviral drugs among patients with virological failure at Week 12</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Resistance to 1st, 2nd and 3rd-line antiretroviral drugs</measure>
    <time_frame>Week 64</time_frame>
    <safety_issue>No</safety_issue>
    <description>Resistance mutations to antiretroviral drugs among patients with virological failure at Week 64</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma antiretroviral drugs concentration</measure>
    <time_frame>Week 12</time_frame>
    <safety_issue>No</safety_issue>
    <description>Plasma antiretroviral drugs concentration at Week 12</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma antiretroviral drugs concentration</measure>
    <time_frame>Week 64</time_frame>
    <safety_issue>No</safety_issue>
    <description>Plasma antiretroviral drugs concentration at Week 64</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">200</enrollment>
  <condition>HIV Infection</condition>
  <arm_group>
    <arm_group_label>Adherence reinforcement before switch to 3rd-line ART</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>adherence reinforcement</intervention_name>
    <description>Directly observed treatment at home (family or relatives DOT); pillboxes; phone calls; SMS; home visits; adherence reinforcement sessions by trained health workers.</description>
    <arm_group_label>Adherence reinforcement before switch to 3rd-line ART</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Antiretroviral Therapy Darunavir/r + Raltegravir + 2 NRTIs (as chosen by the investigators)</intervention_name>
    <description>Second-line ART regimen : ongoing regimen at the time of inclusion will be continued.
Third-line ART regimen : Darunavir/r + Raltegravir + 2 NRTIs (as chosen by the investigators)</description>
    <arm_group_label>Adherence reinforcement before switch to 3rd-line ART</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age &gt;18 years

          -  Documented HIV-1 infection

          -  History of failing a NNRTI-based 1st-line ART

          -  Current PI-based 2nd-line ART &gt;6 months

          -  Plasma HIV-1 RNA &gt;1000 copies/ml

          -  Signed informed consent

        Exclusion Criteria:

          -  HIV-2 infection

          -  Any Severe clinical event under exploration

          -  History of treatment including darunavir or raltegravir.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Serge P. Eholie, MD, MSc, Pr</last_name>
    <role>Principal Investigator</role>
    <affiliation>Service des Maladies Infectieuses et Tropicales,  CHU de Treichville, Abidjan, Côte d'Ivoire</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Roland Landman, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Institut de Médecine et d'Epidémiologie Appliquée - Hôpital Bichat Claude Bernard, Paris, France</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Xavier Anglaret, MD, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Inserm 897, University of Bordeaux, France</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Pierre-Marie Girard, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Infectious Diseases Department, University Hospital Saint Antoine, Paris, France</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Raoul Desmoryl Moh, MD, PHD</last_name>
    <phone>+225 07 82 83 79</phone>
    <email>raoul.moh@pacci.ci</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Aïda Benalcherif</last_name>
    <phone>+33 (1) 40 25 63 65</phone>
    <email>aida.benalycherif@gmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>CHU Sourô Sanou</name>
      <address>
        <city>Bobo-Dioulasso</city>
        <country>Burkina Faso</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Adrien B Sawadogo, MD</last_name>
      <phone>+22620985255</phone>
      <email>sawadogoadrien@yahoo.fr</email>
    </contact>
    <contact_backup>
      <last_name>Jacques Zoungrana, MD</last_name>
      <phone>+22672303821</phone>
      <email>zojacques@yahoo.fr</email>
    </contact_backup>
    <investigator>
      <last_name>Jacques Zoungrana, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre de Prise en Charge et de Formation (CePReF), Association ACONDA</name>
      <address>
        <city>Abidjan</city>
        <country>Côte D'Ivoire</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Eugène Messou, MD, PhD</last_name>
      <phone>+22523462551</phone>
      <email>messou_eugene@yahoo.fr</email>
    </contact>
    <contact_backup>
      <last_name>Ama Anzian, MD</last_name>
      <phone>+22540185774</phone>
      <email>amani_anzian@yahoo.fr</email>
    </contact_backup>
    <investigator>
      <last_name>Amani Anzian, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Service des Maladies Infectieuses et Tropicales (SMIT)</name>
      <address>
        <city>Abidjan</city>
        <country>Côte D'Ivoire</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Emmanuel Bissagnene, MD, Pr</last_name>
      <phone>+22521755960</phone>
      <email>bissagnene@yahoo.fr</email>
    </contact>
    <contact_backup>
      <last_name>Frédéric Ello, MD</last_name>
      <phone>+22521755960</phone>
      <email>ellonogboufrdric@yahoo.fr</email>
    </contact_backup>
    <investigator>
      <last_name>Eboumou Gole, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU Point G</name>
      <address>
        <city>Bamako</city>
        <country>Mali</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Daouda K Minta, MD</last_name>
      <phone>+22320229790</phone>
      <email>douada_minta@yahoo.fr</email>
    </contact>
    <contact_backup>
      <last_name>Abdoulaye Traoré, MD</last_name>
      <phone>+22320229790</phone>
      <email>matraore_cmbko@yahoo.fr</email>
    </contact_backup>
    <investigator>
      <last_name>Mahamadou Fomba, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre d'Ecoute, de Soins, d'Animation et de Conseils (CESAC)</name>
      <address>
        <city>Bamako</city>
        <country>Mali</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Mamadou Cissé, MD</last_name>
      <phone>+22320236477</phone>
      <email>madci@yahoo.fr</email>
    </contact>
    <contact_backup>
      <last_name>Fodié Diallo, MD</last_name>
      <phone>+22366731815</phone>
      <email>fodie10@yahoo.fr</email>
    </contact_backup>
    <investigator>
      <last_name>Konate Tiefing, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU Fann</name>
      <address>
        <city>Dakar</city>
        <country>Senegal</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Moussa Seydi, MD, Pr</last_name>
      <phone>+221338231327</phone>
      <email>seydi_moussa@gmail.com</email>
    </contact>
    <contact_backup>
      <last_name>Mouhamadou B Diallo, MD</last_name>
      <phone>+221776511773</phone>
      <email>mamadoubaila@yahoo.fr</email>
    </contact_backup>
    <investigator>
      <last_name>Nogaye Gaye</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Burkina Faso</country>
    <country>Côte D'Ivoire</country>
    <country>Mali</country>
    <country>Senegal</country>
  </location_countries>
  <link>
    <url>http://anrs.fr/</url>
    <description>Sponsor site</description>
  </link>
  <link>
    <url>http://www.mereva.net/</url>
  </link>
  <verification_date>January 2014</verification_date>
  <lastchanged_date>January 2, 2014</lastchanged_date>
  <firstreceived_date>December 30, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Africa</keyword>
  <keyword>Antiretroviral Treatment</keyword>
  <keyword>Adherence reinforcement</keyword>
  <keyword>Third line ART</keyword>
  <keyword>Second line ART</keyword>
  <keyword>Virologic failure</keyword>
  <keyword>Adults</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>HIV Infections</mesh_term>
    <mesh_term>Acquired Immunodeficiency Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Darunavir</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
